Financial Performance - KORU Medical Systems achieved record Q3 revenues of $10.4 million, a 27% increase compared to the prior year period, driven by the Core SCIg business[6, 20] - The company reported a net loss of $0.8 million but achieved a positive adjusted EBITDA of $0.09 million and generated $0.4 million in cash during Q3[6] - KORU Medical Systems is raising its 2025 revenue guidance to $40.5-$41.0 million, representing a growth of 20%-22%, and reiterating a gross margin of 61%-63%[6] Market and Growth Opportunities - The US SCIg market is forecasted to grow at 9%+ through 2029[8] - KORU Medical Systems has grown its international market share from approximately 10% to approximately 15-20% since 2024, with significant room for further penetration in the ~$60 million global SCIg market[11] Pipeline and Outlook - KORU Medical Systems has 7 collaborations/opportunities with Ig manufacturers, targeting a $450 million Total Ig TAM (Total Addressable Market)[12] - The company plans for 4 new drug additions on the KORU Freedom Infusion System by 2026, expanding internationally and pursuing drug labels independently, targeting a $1.8 billion Total TAM[13] - KORU Medical Systems is progressing with its strategic oncology infusion market entry initiative, with an anticipated market entry in 4Q25/1Q26, targeting a ~$138 million 2025 TAM[18, 19]